Stock Track | Vera Therapeutics Plunges 9% After Pricing $300 Million Stock Offering

Stock Track10-30

Shares of Vera Therapeutics Inc. plummeted over 9% on Monday after the late-stage biotech company announced pricing for a $300 million public offering of its Class A common stock.

Vera said it plans to sell 7.1 million shares at $42 apiece, with underwriters having a 30-day option to purchase an additional 1.1 million shares. The offering is expected to close on October 31st.

The sizable equity raise will dilute existing shareholders but provides Vera with cash to fund ongoing development of its pipeline candidates, including atacicept for autoimmune diseases like IgA nephropathy and lupus nephritis, as well as MAU868 for preventing BK virus infection after kidney transplants.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185947352?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 08:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185947352","market":"us","top_or_hot":-1,"title":"Stock Track | Vera Therapeutics Plunges 9% After Pricing $300 Million Stock Offering","media":"Stock Track","content":"<p>Shares of Vera Therapeutics Inc. plummeted over 9% on Monday after the late-stage biotech company announced pricing for a $300 million public offering of its Class A common stock.</p>\n\n<p>Vera said it plans to sell 7.1 million shares at $42 apiece, with underwriters having a 30-day option to purchase an additional 1.1 million shares. The offering is expected to close on October 31st.</p>\n\n<p>The sizable equity raise will dilute existing shareholders but provides Vera with cash to fund ongoing development of its pipeline candidates, including atacicept for autoimmune diseases like IgA nephropathy and lupus nephritis, as well as MAU868 for preventing BK virus infection after kidney transplants.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vera Therapeutics Plunges 9% After Pricing $300 Million Stock Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vera Therapeutics Plunges 9% After Pricing $300 Million Stock Offering\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-30 08:28 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Vera Therapeutics Inc. plummeted over 9% on Monday after the late-stage biotech company announced pricing for a $300 million public offering of its Class A common stock.\nVera said it plans ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VERA","symbol_name":"Vera Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1185947352","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185947352","pubTimestamp":1730248104,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Vera Therapeutics Inc. plummeted over 9% on Monday after the late-stage biotech company announced pricing for a $300 million public offering of its Class A common stock.Vera said it plans to sell 7.1 million shares at $42 apiece, with underwriters having a 30-day option to purchase an additional 1.1 million shares. The offering is expected to close on October 31st.The sizable equity raise will dilute existing shareholders but provides Vera with cash to fund ongoing development of its p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VERA":"Vera Therapeutics, Inc."},"translate_title":"Vera Therapeutics定价3亿美元股票发行后股价暴跌9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERA":1},"content_text":"Shares of Vera Therapeutics Inc. plummeted over 9% on Monday after the late-stage biotech company announced pricing for a $300 million public offering of its Class A common stock.\nVera said it plans to sell 7.1 million shares at $42 apiece, with underwriters having a 30-day option to purchase an additional 1.1 million shares. The offering is expected to close on October 31st.\nThe sizable equity raise will dilute existing shareholders but provides Vera with cash to fund ongoing development of its pipeline candidates, including atacicept for autoimmune diseases like IgA nephropathy and lupus nephritis, as well as MAU868 for preventing BK virus infection after kidney transplants.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185947352"}